The role of lymphocyte-monocyte ratio on axial spondyloarthritis diagnosis and sacroiliitis staging

Jing Wang
Taizhou Hospital of Zhejiang Province

Jinyu Su
Taizhou Hospital of Zhejiang Province

Yuan Yuan
Taizhou Hospital of Zhejiang Province

Xiaxia Jin
Taizhou Hospital of Zhejiang Province

Bo Shen
Taizhou Hospital of Zhejiang Province

Guoguang Lu (✉ lugg@enzemed.com)
Taizhou Hospital of Zhejiang Province

Research article

Keywords: Axial spondyloarthritis (axial SpA), Lymphocyte-monocyte ratio (LMR), X-ray, Disease activity, Stage

DOI: https://doi.org/10.21203/rs.2.21180/v5

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Axial spondyloarthritis (axial SpA) is a chronic inflammatory disorder could lead to disability due to the failure of timely treatment. The role of lymphocyte-to-monocyte ratio (LMR) in axial SpA remains unclear. The aim of this study was to investigate the role of LMR in axial SpA diagnosis, disease activity classification and sacroiliitis staging.

**Methods:** Seventy-eight axial SpA patients [51 males and 27 females; mean age 41.0 (29–52) years] and 78 healthy controls (HCs) [55 males and 23 females; mean age 40 (30-53) years] were enrolled in this study. The diagnosis of axial SpA was performed according to the New York criteria or the Assessment of Spondyloarthritis international Society (ASAS) classification criteria, whereas the staging of sacroiliitis in axial SpA patients was determined by X-ray examination. Comparisons of LMR levels between groups were performed using t test. Pearson or Spearman correlation analysis were used to assess correlations between LMR and other indicators. Receiver operating characteristic (ROC) curves were used to determine the role of LMR in the diagnosis of axial SpA.

**Results:** Higher neutrophil-to-lymphocyte ratio (NLR), red blood cell distribution width (RDW), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels and lower red blood cell (RBC), hemoglobin (Hb), Hematocrit (Hct), LMR, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL) and albumin/globulin (A/G) levels were noted in axial SpA patients compared to HCs. Positive correlations were observed between LMR and RBC, Hb, Hct and A/G, whereas negative correlations were found between LMR and NLR, PLR, AST, and TBIL \((P< 0.05)\). ROC curves showed that the area under the curve (AUC) for LMR in the diagnosis of ankylosing spondylitis was 0.803 \((95\% \ CI = 0.734-0.872)\) with a sensitivity and specificity of 62.8% and 87.2%, respectively, and the AUC (95% CI) for the combination of ESR, CRP and LMR was 0.975 (0.948-1.000) with a sensitivity and specificity of 94.9% and 97.4%, respectively. LMR levels were lower \((P<0.05)\) and significant differences in LMR values were observed among different stages \((P<0.05)\).

**Conclusions:** Our study suggested that LMR might be an important inflammatory marker to identify axial SpA and assess disease activity and X-ray stage of sacroiliitis.

**Background**

Axial spondyloarthritis (axial SpA), an immune-mediated chronic inflammatory rheumatic disease with unknown etiology, mainly affects the axial bone and articular structures, but also enthesitis, arthritis and dactylitis[1]. The prevalence of axial SpA is approximately 0.2-0.3%, and this condition primarily occurs in males aged 20-30 years. Without effective treatment, severe disabilities could develop in approximately one-third of patients[2]. To date, the pathophysiology of axial SpA is not completely understood. Risk factors associated with heredity factors, immunity and inflammation are considered the most important factors in the pathogenesis of axial SpA. The Assessment in Spondyloarthritis International Society
(ASAS) provides recommendations for the management of axial SpA, including classification criteria, magnetic resonance imaging (MRI), X-rays and laboratory indicators for sacroiliac joints and the spine.

In current clinical practice, HLA-B27 is helpful in diagnosis of axial SpA given its high prevalence (90%-95%) in axial SpA and its direct role in the onset of axial SpA [3]. In addition to HLA-B27, imaging modalities such as X-ray, computed tomography (CT), ultrasonography and MRI are typically employed in the diagnosis of axial SpA [4]. X-ray imaging is used to diagnose typical sacroiliitis, but early sacroiliitis is easily missed by this methodology. CT can satisfactorily reveal the sacroiliac joint space and articular surface bone, and reveal slight articular surface bone erosion and subchondral cystic change that X-rays cannot show. Ultrasonography can show peripheral arthritis and enthesitis, but it cannot evaluate axial manifestations. MRI can directly display articular cartilage, and is superior to CT in the early detection of sacroiliac joint cartilage changes, evaluation of sacroiliitis conditions and curative effect judgments.

Different imaging modalities have different characteristics and unique advantages and limitations, including radioactive properties, relative costs, long turnaround time and limited use in specific patients (such as pregnant women). Therefore, specific and sensitive biochemical markers for auxiliary diagnosis, treatment guidance and prognosis monitoring of axial SpA are urgently needed.

Bath ankylosing spondylitis disease activity index (BASDAI) and ankylosing spondylitis disease activity score (ASDAS) are common disease activity scoring systems for axial SpA [6]. Among them, BASDAI is based on the patient's own feelings and do not include the doctor's evaluation of the patient's condition and laboratory indicators. ASDAS reflects the subjective feelings of patients and doctors, and includes inflammatory indicators, so this metric is more suitable for clinical practice. However, due to other complications, the increase in inflammatory markers can affect the evaluation of disease activity. Commonly used inflammatory markers, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) [7], have been verified to be related to axial SpA disease severity. ESR × duration of disease and CRP × duration of disease exhibit a good correlation with poor physical activity of axial SpA patients [8]. In recent years, some new inflammatory markers, such as the neutrophil to lymphocyte ratio (NLR) and red blood cell distribution width (RDW), have also been found to be associated with axial SpA disease activity. In axial SpA patients, NLR exhibits a good correlation with ESR and CRP, and increased NLR was found in patients with high disease activity [9]. In addition, different NLR levels were found in patients subject to different treatments, such as anti-TNF-alpha therapy, and nonsteroidal anti-inflammatory drugs [10]. Moreover, a significant difference in RDW was noted between patients with BASDAI index > 4 and < 4. RDW was positively correlated with BASDAI index as well as ESR and CRP levels [9]. Based on these findings, routine blood test indexes could represent potential resource for novel and effective marker exploration for axial SpA.

Like RDW and NLR, the Lymphocyte to monocyte ratio (LMR), is also a common blood routine indicator. LMR has been a subject of great interest in a wide range of fields such as inflammation, immunology and carcinoma for a long period of time. Recent data from several studies suggested that LMR was associated with diagnostic, pretreatment and prognostic statue of diseases. A genome-wide association study has confirmed that mutations in ITGA4 and HLA-DRB1 genes could affect LMR levels, and these
genes have been widely recognized as susceptibility genes for autoimmune diseases, such as rheumatoid arthritis (RA)\[^{11}\], suggesting their potential value in axial SpA diagnosis and prognostic evaluation.

To date, few studies have investigated the association between LMR and axial SpA. Therefore, the aim of this study was to explore the diagnostic value of LMR in axial SpA and its role in reflecting disease activity and X-ray staging.

**Methods**

**Patients with axial SpA**

A total of 78 patients with axial SpA [51 males and 27 females; mean age 41.0 (29–52) years] were enrolled in this cross-sectional study. These patients received treatment at the Department of Endocrinology and Rheumatology, Taizhou Hospital (Zhejiang, China). All patients fulfilled the axial SpA criteria prescribed by the New York criteria of 1984\[^{12}\] or the ASAS classification criteria of 2009\[^{13}\]. All patients were exclusively treated by nonsteroidal anti-inflammatory drugs (NSAIDs). For NSAIDs are the first choice for axial SpA patients, and other drugs, such as sulfasalazine, methotrexate, and biological agents may affect the hematopoietic function of bone marrow and have a greater impact on peripheral blood cell counts. Patients with autoimmune diseases such as Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and psoriasis, malignant diseases, end-stage kidney diseases, liver diseases, acute myocardial infarction, hypertension, diabetes, cerebrovascular diseases were excluded.

**Sacroiliitis X-ray staging of the axial SpA Patients**

The stage of sacroiliitis was assessed using X-ray and staged from I to IV as follows: stage I with suspicious sacroiliitis; stage II with vague margin of sacroiliac joint, slightly sclerotic and minimally invasive lesions, and unchanged joint space; stage III with moderate or progressive sacroiliitis, accompanied by one or more following changes, including sclerosis of proximal articular area, narrowing/widening of joint space, bone destruction or partial ankylosis; and stage IV with complete joint fusion or ankylosis with or without sclerosis. According to the sacroiliitis classification, early-stage (Stage I and II) patients were defined as non-radiographic axial SpA group, and late-stage (Stage III and IV) patients were defined as radiographic axial SpA group.

**Healthy Controls**

Healthy controls (HCs) included 55 males and 23 females with a mean age of 40 (30–53) years. These subjects were selected from individuals who underwent a physical examination at the Physical Examination Center of Taizhou Hospital (Zhejiang, China) and the sex and age of these subjects were matched with axial SpA patients. All subjects were healthy without any disease and were not taking drugs that affect bone metabolism, such as hormone replacement therapy.
Biological detection and Imaging system

Fasting blood samples were obtained from all included subjects, whereas X-ray imaging was acquired simultaneously from axial SpA patients. Blood routine tests were assessed using the Mindray BC6800-plus (China) automatic blood analyzer. ESR was detected using the ALifax Tes1 (Italy) automatic blood analyzer. CRP was detected by Immage 800 (Beckman Coulter, USA). ALT, AST, TBIL and Alb/Globin (A/G) were detected using the AU5800 (Beckman Coulter, USA) automatic biochemical analyzer. X-ray images were obtained using the Digital X-ray imaging system (DR) (Philips, Holland).

Statistical analyses

All statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL), and all graphs were drawn using GraphPad Prism 8. Kolmogorov-smirnov test was used to check the normality of the distribution. Continuous variables that conform to a normal distribution were expressed as the mean ± standard deviation, and t tests were used for comparison between groups. The median (P25-P75) was used for non-normal distributions, and Mann Whitney U test and Kruskal Wallis tests were used for comparisons between groups. Categorical variables were expressed as numbers (percentage), and comparisons between groups were performed using chi-square or Fisher's exact tests (the theoretical frequency in one or more square is less than 5). Receiver operating characteristic (ROC) curve analysis with calculation of area under curve (AUC) and 95% confidence interval (CI) was used to determine the role of LMR in the diagnosis of axial SpA. Moreover, the optimal cut-off value was calculated using Youden's index based on specificity and sensitivity. The correlations between LMR and other indicators were assessed using Pearson correlation or Spearman correlation analysis for normal and non-normally distributed data, respectively. P ≤0.05 was considered to indicate statistical significance.

Results

Baseline characteristics of the included subjects

Seventy-eight axial SpA patients [51 males, 27 females; mean age (range): 41 (29–52) years] and 78 healthy controls [55 males and 23 females with a mean age (range) of 40 (30–53) years] were included in this study. Blood-routine test indexes, ESR and the serum levels of CRP in both groups were assayed, and compared between axial SpA and HCs. Higher NLR, RDW, PLR, MPV, ESR, and CRP and lower RBC, Hb, Hct, LMR, ALT, AST, TBIL and A/G levels were noted in the axial SpA group compared to healthy controls \( (P<0.05) \), and the differences were significant. (Table 1)

Table 1. Comparison of baseline characteristics in axial SpA patients and healthy controls
Characteristics & Axial SpA (n1=78) & Healthy controls (HCs) (n2=78) & P-value \\
Age (years) & 41 (29-52) & 40 (30-53) & 0.783 \\
Sex (Male, %) & 51 (65.4) & 55 (70.5) & 0.607 \\
WBC (×10^9/L) & 7.2±2.3 & 6.1±1.2 & <0.001 \\
LMR & 3.81±1.87 & 5.98±1.65 & <0.001 \\
NLR & 2.63 (1.71-3.55) & 1.67 (1.38-2.11) & <0.001 \\
RBC (×10^{12}/L) & 4.21±0.72 & 5.03±0.42 & <0.001 \\
Hb (g/L) & 116 (101-38) & 150 (140-159) & <0.001 \\
Hct & 0.361±0.061 & 0.450±0.038 & <0.001 \\
RDW (%) & 13.4 (12.5-14.3) & 12.5 (12.2-12.8) & <0.001 \\
MPV (fl) & 152.2 (123.2-201.4) & 124.6 (102.8-154.6) & <0.001 \\
ESR (mm/h) & 32.1 (14.1-76.0) & 2.9 (1.5-4.9) & <0.001 \\
CRP (mg/L) & 16.5 (10.0-25.3) & 22.0 (22.0-26.3) & <0.001 \\
ALT (U/L) & 18.5 (15.0-25.5) & 18.5 (15.0-25.5) & 0.001 \\
AST (U/L) & 1.4 (1.2-1.6) & 1.8 (1.7-2.0) & <0.001 \\
TBIL (μmol/L) & 9.34 (6.35-14.23) & 15.85 (13.08-19.52) & <0.001 \\

WBC: White blood cells; LMR: Lymphocyte-monocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; RBC: Red blood cells; Hb: Hemoglobin; Hct: Hematocrit; RDW: Red cell distribution width; PLR: Platelet to lymphocyte ratio; MPV: Mean platelet volume; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ALT: Alanine aminotransferase; AST: Aspartate Aminotransferase; A/G: Albumin/globulin ratio; TBIL: Total bilirubin.

**Correlation between LMR and other laboratory parameters in axial SpA patients**

We further analyzed the correlation between LMR and other laboratory parameters in axial SpA patients. Positive correlations were observed between LMR and RBC (r = 0.387, P < 0.001), Hb (r = 0.339, P = 0.002), Hct (r = 0.368, P < 0.001) and A/G (r = 0.278, P = 0.042), whereas negative correlations were observed between LMR and NLR (r = -0.736, P < 0.001), PLR (r = -0.383, P = 0.004) and TBIL (r = -0.277, P = 0.042). (Figure 1)

**ROC Curve**

ROC curves were used to explore the efficiency of clinical indicators in the diagnosis of axial SpA. Indicators with AUC values greater than 0.600 are shown in Tab. 2. The AUC (95% CI) for LMR was 0.803 (0.734-0.872), and similar values were noted for ESR and CRP [0.937(0.895-0.978), 0.899(0.845-0.954)]. Based on the optimal cutoff values (LMR=4.26) calculated from the ROC curves, a sensitivity of 62.8% and a specificity of 87.2% was obtained. The AUC (95% CI) for ESR, CRP and LMR in the combined diagnosis of axial SpA were 0.975(0.948-1.000), with the sensitivity and specificity of 94.9% and 97.4% (Fig.2).
Table 2. Comparison of areas under the ROC curve of clinical indicators for diagnosis of axial SpA

| Indicator | AUC             | P-value |
|-----------|-----------------|---------|
| ESR (mm/h)| 0.937 (0.895-0.978) | P < 0.001 |
| CRP (mg/L)| 0.899 (0.845-0.954)  | P < 0.001 |
| LMR       | 0.803 (0.734-0.872)  | P < 0.001 |
| RDW (%)   | 0.773 (0.696-0.849)  | P < 0.001 |
| NLR       | 0.718 (0.634-0.801)  | P < 0.001 |
| PLR       | 0.687 (0.602-0.772)  | P < 0.001 |
| A/G       | 0.648 (0.548-0.747)  | 0.002   |
| MPV (fl)  | 0.639 (0.550-0.729)  | 0.003   |
| ESR+CRP+LMR| 0.975 (0.948-1.000) | P < 0.001 |

Comparison of characteristics between the low X-ray stage and high X-ray stage group

A total of 43 and 35 patients were included in the non-radiographic axial SpA group (stage I-II) and radiographic axial SpA group (stage III), respectively. The comparison results revealed higher WBC (8.0±2.5 vs. 6.5 ± 2.0) and NLR [3.00 (1.85-5.60) vs. 2.38 (1.62-3.10)] levels and lower LMR levels (3.32±1.77 vs. 4.21±1.88) in the radiographic axial SpA group compared to the non-radiographic axial SpA group.

Table 3. Comparison of characteristics between the non-radiographic axial SpA and radiographic axial SpA groups

| Indicator | Non-radiographic axial SpA (n1=43) | Radiographic axial SpA (n2=35) | P-value |
|-----------|-----------------------------------|-------------------------------|---------|
| WBC (×10^9/L) | 6.5 ± 2.0                         | 8.0±2.5                       | 0.007   |
| CRP (mg/L)   | 31.0 (12.8-69.8)                   | 34.5 (14.7-80.9)              | 0.786   |
| ESR (mm/h)   | 40 (18-83)                         | 35 (20-74)                    | 0.637   |
| TBIL(μmol/L) | 9.00 (6.10-13.25)                  | 9.80 (6.40-14.85)             | 0.271   |
| NLR          | 2.38 (1.62-3.10)                   | 3.00 (1.85-5.60)              | 0.046   |
| PLR          | 153.1 (128.1-201.1)                | 164.0 (112.4-217.5)           | 0.964   |
| LMR          | 4.21±1.88                         | 3.32±1.77                     | 0.035   |
| RBC (×10^12/L)| 4.34±0.65                         | 4.05±0.77                     | 0.078   |
| Hb (g/L)     | 117.0 (103.0-140.0)                | 115.0 (94.0-133.0)            | 0.250   |
| Hct          | 0.370±0.052                        | 0.351±0.070                   | 0.198   |
| ALT (U/L)    | 16.0 (8.0-27.0)                    | 17.0 (11.0-21.0)              | 0.889   |
| AST (U/L)    | 17.0 (13.0-22.5)                   | 19.0 (15.5-32.5)              | 0.152   |
| A/G          | 1.4±0.3                            | 1.3±0.3                       | 0.371   |
WBC: White blood cells; LMR: Lymphocyte-monocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; RBC: Red blood cells; Hb: Hemoglobin; Hct: Hematocrit; RDW: Red cell distribution width; PLR: Platelet to lymphocyte ratio; MPV: Mean platelet volume; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ALT: Alanine aminotransferase; AST: Aspartate Aminotransferase; A/G: Albumin/globulin ratio; TBIL: Total bilirubin.

**LMR in different X-ray stages of axial SpA Patients**

Further staging of axial SpA patients based on X-ray imaging resulted in the allocation of 16, 27, 30 and 5 patients into stages I, II, III and IV, respectively. There were no statistical differences in LMR values among axial SpA patients of stages I, II and III, but LMR values of stage IV patients were lower than other stages (P<0.01). (Figure 3).

**Discussion**

In previous studies, recently developed inflammatory and immunological indicators such as NLR and the platelet-to-lymphocyte ratio (PLR) have been verified as diagnostic makers of disease activity and severity in various disorders. Peng et al. indicated that the combined use of NLR, PLR and CEA could represent a good diagnostic biomarkers for colorectal cancer, and positive correlations were found between the TNM stage and NLR or PLR\[15\]. In addition, Zhao et al. also observed that NLR was correlated with knee recurrence after arthroscopic surgery combined with local radiotherapy [16]. A recent study of RA patients with and without rheumatoid arthritis-associated interstitial lung disease (RA-ILD) by Chen et al. revealed that PLR and NLR exhibited a statistically significant positive correlation with DAS28 and PLR could be used to diagnose RA and RA-ILD and distinguish RA-ILD patients from RA patients and healthy subjects[17].

In recent years, another indicator LMR has attracted considerable attention in the diagnosis and prognosis of many diseases such as cancers or various immunological diseases. Rajwa et al. found that urothelial bladder cancer patients treated with radical cystectomy with lower LMR values exhibited a greater risk for developing postoperative in-hospital complications[18]. Du et al. showed that the LMR was an inflammatory marker that is effective in disease activity evaluation in patients with RA and RA differentiation from other arthritis condition[19].

The present study revealed a decreased LMR in axial SpA patients compared to healthy controls, especially in axial SpA patients with high X-ray stages. Furthermore, the correlations between LMR and other axial SpA related indicators revealed that LMR was positively correlated with RBC, Hb, Hct and A/G and negatively correlated with NLR, PLR, AST and TBIL.

Anemia is a common phenomenon in the process of chronic inflammation and is also found in axial SpA patients, and the mechanisms were attributed to the inhibitory effects of cytokines secretion. Tumor necrosis factor alpha (TNF-α) could block the effects of Erythropoietin (EPO) on CD34(+) hematopoietic stem/progenitor cells[20]. Increased hemoglobin level were observed in axial SpA patients with significant
improvement of physical function and fatigue [21]. Thus, hemoglobin levels could reflect axial SpA activity and severity. Specifically, reduced Hb levels indicate reduced disease severity.

As a major component in serum protein, serum albumin was used to reveal long-standing malnutrition and was also associated with systemic inflammation[22]. Globulin is the carrier of sex hormones, and globulin levels combined with levels of pro-inflammatory proteins (including complement components, immunoglobulin, CRP, interleukin, TNF) are reflective of the inflammatory state[23]. A/G is based on serum albumin and globulin levels and reflects immune nutritional status and systemic inflammatory reactions with more accuracy compared with either indicator alone. A higher A/G value indicates a good malnutrition status and low hormone levels. Besides, Lin et al also showed that a low A/G level was significantly correlated with high total bilirubin levels but low hemoglobin levels [24]. These results were consistent with the results obtained in this study.

Lymphocytes play an important role in immunology. Although different subsets of T cells are associated with poor tumor prognosis [25, 26], high absolute lymphocyte counts are associated with good prognosis in gastric cancer patients [27]. An increased number of monocytes was associated with poor prognosis in various types of tumors[28, 29].

Monocytes could differentiate into tumor-associated macrophages (TAMs) in the tumor microenvironment[30]. TAMs could promote tumor angiogenesis and tumor growth by secreting TNF-α[31]. Therefore, LMR may be associated with a good axial SpA prognosis because a higher of LMR could result in reduced inhibitory effects of TNF-α on EPO secretion as well as higher hemoglobin levels and A/G ratios. In contrast, lower NLR, PLR, total bilirubin levels and direct bilirubin levels were also observed, supporting the results of this study.

Liver toxic effects could result from systemic rheumatic diseases and therapeutic drugs. Hepatic involvement is a severe type of extra-articular manifestations in various rheumatic diseases. Hepatotoxicity is commonly observed with the use of NSAIDs and disease-modified anti-rheumatic drugs (DMARD) as immunosuppressants[32]. In our study, we only included axial SpA patients who were treated by NSAIDs; Therefore, the negative correlation between LMR and AST was reasonable.

Regarding the correlations we observed between axial SpA and LMR, we further discussed the diagnostic value of LMR in axial SpA prognosis. ROC curve analysis showed that LMR had a high diagnostic value for axial SpA second only to ESR and CRP. The combined diagnostic AUC of LMR, ESR and CRP for axial SpA was 0.975 with a sensitivity and specificity of 94.9% and 97.4%, respectively. Based on X-ray staging, axial SpA patients were divided into the non-radiographic axial SpA and radiographic axial SpA groups. WBC and NLR levels were higher in the radiographic axial SpA groups, whereas LMR levels were lower. Based on these observations, it can be inferred that LMR is associated with the X-ray stage of sacroiliitis in axial SpA patients.

The relationship between LMR and X-ray staging in axial SpA is rarely reported in previous publications. In our research, we classified axial SpA patients as stage I to IV according to X-ray imaging to discuss the
associations between LMR and the severity of sacroiliitis. The value of LMR decreased as X-ray staging increased, indicating the role of LMR in determining axial SpA severity.

The main limitation of our study was it only assessed patients from a single center. Therefore, multicenter prospective study is needed for further verification of our results. Secondly, we could not obtain scoring criteria related to axial SpA activity such as BASDAI and ASDAS activity indexes, given the lack of or incomplete clinical datas of axial SpA patients. Third, the sample size was relatively small given the low prevalence and we only included axial SpA patient treated by NSAIDs in the present study. Fourth, most of axial SpA patients included in the study exhibited a lower stage of activity and disease severity, and more sensitive imaging techniques are needed.

**Conclusion**

In conclusions, we found that LMR is a rapid, cheap and nonradioactive parameter that can be used to auxiliary diagnosis axial SpA. Furthermore, LMR may represent an important tool for the assessment of disease activity and X-ray stage of sacroiliitis in axial SpA patients. However, prospective studies on large sample sizes are needed for further validation.

**Abbreviations**

Axial SpA: Axial Spondyloarthritis; LMR: Lymphocyte-monocyte ratio; HCs: Healthy controls; NLR: Neutrophil lymphocyte ratio; RDW: Red blood cell distribution width; PLR: Platelet lymphocyte ratio; MPV: Mean platelet volume; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; RBC: Red blood cell; Hb: Hemoglobin; Hct: Hematocrit; LMR: Lymphocyte-monocyte ratio; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; A/G: Albumin/globulin; AUC: Area under curve; CI: Confidential interval; TAM: Tumor associated macrophages; TNF-α: Tumor necrosis factor alpha; EPO: Erythropoietin; NSAIDs: Non-steroidal anti-inflammatory drugs; DMARD: disease-modified anti-rheumatic drugs; RA: rheumatoid arthritis.

**Declarations**

- Ethics approval and consent to participate: Medical ethics committee of Taizhou Hospital of Zhejiang Province.
- Consent for publication: Not applicable.
- Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
- Competing interests: The authors declare that they have no financial or other conflicts of interest in relation to this research and its publication.
- Funding: This study was supported by grants from Taizhou Science and Technology Plan (1802ky18) (Zhejiang, China). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.

- Authors’ contributions: JW, GL conceived, designed and coordinated the study, participated in acquisition and interpretation of data, and drafted the manuscript. X J participated in acquisition of data. Y Y participated in blood and urine determination levels and the interpretation of data. JS, BS participated in the revision of manuscript. All authors have read and approved the manuscript in the “Authors’ contributions” section.

- Acknowledgements: This work was supported by grants from Taizhou Municipal Science and Technology Bureau (CN) (1802KY18). We thank the Endocrinology Department of Taizhou Hospital of Zhejiang Province for their support to our research.

- Authors’ Information: Jing Wang: Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province; Jinyu Su: Department of Pharmacy, Taizhou Hospital of Zhejiang Province; Yuan Yuan: Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province; Xiaxia Jin: Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province; Bo Shen: Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province; Guoguang Lu: Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province.

References

1. Xu Z, Wang X, Zheng Y. Screening for key genes and transcription factors in ankylosing spondylitis by RNA-Seq. Exp Ther Med 2018; 15(2):1394-1402.

2. Arévalo M, Gratacós Masmitjà J, Moreno M, Calvet J, Orellana C, Ruiz D,et al. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. Arthritis research & therapy 2018; 20(1):221.

3. Stolwijk C, Onna MV, Boonen A, Tubergen AV. The global prevalence of spondyloarthritis: A systematic review and meta-regression analysis. Arthritis Care Research 2015; 68(9):1320-1331.

4. Bradbury LA, Hollis KA, Gautier B, Shankaranarayana S, Robinson PC, Saad N,et al. Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis. The Journal of rheumatology 2018; 45(6):771-778.

5. Ostergaard M, Lambert RGW. Imaging in ankylosing spondylitis. Ther Adv Musculoskelet Dis 2012; 4(4):301-311.

6. Fallahi S, Jamshidi AR, Gharibdoost F, Mahmoud MI, Paragomi P, Nicknam MH,et al. Urolithiasis in ankylosing spondylitis: Correlation with Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis metrology index (BASMI). Caspian J Intern Med 2012; 3(4):508-513.

7. Schneeeberger EE, Zamora N, Citera G. SASDAS (simplified version of ankylosing spondylitis disease activity score)-ESR performance and development of SASDAS-CRP and their agreement with ASDAS-ESR and ASDAS-CRP in patients with ankylosing spondylitis. Clinical rheumatology 2016; 35(11):2865-2866.
8. Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. The clinical usefulness of ESR, CRP, and
disease duration in ankylosing spondylitis: the product of these acute-phase reactants and disease
duration is associated with patient's poor physical mobility. Rheumatol Int 2015; 35(7):1263-1267.

9. Mercan R, Bitik B, Tufan A, Bozbulner UB, Atas N, Ozturk MA, et al. The Association Between
Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing
Spondylitis. Journal of clinical laboratory analysis 2016; 30(5):597-601.

10. Gökmen F, Akbal A, Reşorlu H, Gökmen E, Güven M, Aras AB, et al. Neutrophil-Lymphocyte Ratio
Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis. Journal of
clinical laboratory analysis 2015; 29(4):294-298.

11. Lin BD, Willemsen G, Fedko IO, Jansen R, Penninx B, de Geus E, et al. Heritability and GWAS Studies
for Monocyte-Lymphocyte Ratio. Twin Res Hum Genet 2017; 20(2):97-107.

12. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis.
A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27(4):361-368.

13. Rudwaleit M, Braun J, Sieper J, Assessment of SpondyloArthritis international S. [ASAS classification
criteria for axial spondyloarthritis]. Z Rheumatol 2009; 68(7):591-593.

14. Ostergaard M, Jacobsson LT, Schaufelberger C, Hansen MS, Bijlsma JW, Dudek A, et al. MRI
assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-
blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis
2015; 74(6):1156-1163.

15. Peng HX, Yang L, He BS, Pan YQ, Ying HQ, Sun HL, et al. Combination of preoperative NLR, PLR and
CEA could increase the diagnostic efficacy for I-III stage CRC. Journal of clinical laboratory analysis
2017; 31(5):e22075.

16. Zhao G, Wang J, Xia J, Wei Y, Wang S, Huang G, et al. The predictive value of preoperative neutrophil-
lymphocyte ratio (NLR) on the recurrence of the local pigmented villonodular synovitis of the knee
joint. BMC Musculoskelet Disord 2018; 19(1):339.

17. Chen Q, Chen D-Y, Xu X-Z, Liu Y-Y, Yin T-T, Li D. Platelet/Lymphocyte, Lymphocyte/Monocyte, and
Neutrophil/Lymphocyte Ratios as Biomarkers in Patients with Rheumatoid Arthritis and Rheumatoid
Arthritis-Associated Interstitial Lung Disease. Med Sci Monit 2019; 25:6474-6481.

18. Rajwa P, Zyczkowski M, Paradysz A, Bujak K, Bryniarski P. Evaluation of the prognostic value of LMR,
PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev
Med Pharmacol Sci 2018; 22(10):3027-3037.

19. Du J, Chen S, Shi J, Zhu X, Ying H, Zhang Y, et al. The association between the lymphocyte-monocyte
ratio and disease activity in rheumatoid arthritis. Clin Rheumatol 2017; 36(12):2689-2695.

20. Grigorakaki C, Morceau F, Chateauvieux S, Dicato M, Diederich M. Tumor necrosis factor alpha-
mediated inhibition of erythropoiesis involves GATA-1/GATA-2 balance impairment and PU.1 over-
exression. Biochem Pharmacol 2011; 82(2):156-166.

21. Braun J, van der Heijde D, Doyle MK, Han C, Deodhar A, Inman R, et al. Improvement in hemoglobin
levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 2009;
22. McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001; 39(2):210-213.

23. Zhang B, Yu W, Zhou LQ, He ZS, Shen C, He Q, et al. Prognostic Significance of Preoperative Albumin-Globulin Ratio in Patients with Upper Tract Urothelial Carcinoma. PLoS ONE 2015; 10(12):e0144961.

24. Lin Q, Lin ZH, Chen J, Lin JX, Li X, Jiang JR, et al. Prognostic significance of preoperative albumin-to-globulin ratio in patients with cholangiocarcinoma. Curr Res Transl Med 2017; 65(2):83-87.

25. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V, et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 2015; 194(7):3475-3486.

26. Shitara K, Nishikawa H. Regulatory T cells: a potential target in cancer immunotherapy. Ann N Y Acad Sci 2018; 1417(1):104-115.

27. Feng F, Zheng G, Wang Q, Liu S, Liu Z, Xu G, et al. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. BMC Gastroenterol 2018; 18(1):148.

28. Shigeta K, Kosaka T, Kitano S, Yasumizu Y, Miyazaki Y, Mizuno R, et al. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy. Ann Surg Oncol 2016; 23(12):4115-4122.

29. Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol 2012; 124(1):92-97.

30. Azarkeivan A, Karimi G, Shaiegan M, Maghsudlu M, Tabbaroki A. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect). Pediatr Hematol Oncol 2009; 26(4):195-201.

31. Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol 2017; 10(1):58.

32. Capkin E, Karkucak M, Cosar AM, Ak E, Karaca A, Gokmen F, et al. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study. Int J Rheum Dis 2015; 18(5):548-552.